Near Completely Humanized Liver in Mice Shows Human-type Metabolic Responses to Drugs

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2004 Aug 28

PMID 15331414

Citations 159

Authors

Chise Tateno

Yasumi Yoshizane

Naomi Saito

Miho Kataoka

Rie Utoh

Chihiro Yamasaki

Asato Tachibana

Yoshinori Soeno

Kinji Asahina

Hiroshi Hino

Toshimasa Asahara

Tsuyoshi Yokoi

Toshinori Furukawa

Katsutoshi Yoshizato

Affiliations

Soon will be listed here.

Abstract

Human hepatocytes were transplanted into urokinase-type plasminogen activator-transgenic SCID mice (uPA/SCID mice), which are immunodeficient and undergo liver failure. The transplanted cells were characterized in terms of their in vivo growth potential and functions. The human hepatocytes progressively repopulated the murine host liver. However, the recipients died when the replacement index (RI) of the human hepatocytes exceeded 50%. The hosts (chimeric mice) survived at RI >50% when treated with a drug that has anti-human complement factor activity, and these mice developed livers with RI values as high as 96%. In total, 36 chimeric mice were generated, and the rate of successful engraftment was as high as 92%. The yield of chimeric mice with RI >70% was 32%. The human hepatocytes in the murine host liver expressed mRNAs for a variety of human cytochrome P450 (hCYP) subtypes, in a manner that was similar to the donor liver. The mRNAs for hCYP3A4 and hCYP1A1/2 were induced in the liver in a CYP type-specific manner when the mice were treated with rifampicin and 3-methylcholanthrene, respectively. These results indicate that human hepatocytes that propagate in mice retain their normal pharmacological responses. We conclude that the chimeric mouse developed in the present study is a useful model for assessing the functions and pharmacological responses of human hepatocytes.

Citing Articles

Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease.

Morioka S, Sanoh S, Ishida Y, Furukawa S, Ogawa Y, Kotake Y Arch Toxicol. 2025; .

PMID: 39979474 DOI: 10.1007/s00204-025-03986-5.

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver.

Karlsson I, Ekdahl A, Etchingham-Coll H, Li X, Ericsson C, Ahlqvist M Int J Mol Sci. 2025; 26(3).

PMID: 39940909 PMC: 11818726. DOI: 10.3390/ijms26031141.

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene.

Zhang M, Mouzannar K, Zhang Z, Teraoka Y, Piotrowski J, Ishida Y PLoS Pathog. 2025; 21(1):e1012803.

PMID: 39787208 PMC: 11717313. DOI: 10.1371/journal.ppat.1012803.

Generation of Replication-Competent Hepatitis B Virus Harboring Tagged Polymerase for Visualization and Quantification of the Infection.

Morita C, Wada M, Ohsaki E, Kimura-Ohba S, Ueda K Microbiol Immunol. 2024; 69(1):43-58.

PMID: 39620377 PMC: 11701411. DOI: 10.1111/1348-0421.13183.

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver.

Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H Viruses. 2024; 16(11).

PMID: 39599858 PMC: 11598975. DOI: 10.3390/v16111743.

References

Tateno C, Yamasaki C, Sato H, Yoshizato K . Heterogeneity of growth potential of adult rat hepatocytes in vitro. Hepatology. 1999; 31(1):65-74. DOI: 10.1002/hep.510310113. View

Ino Y, Sato T, Suzuki S, Iwaki M, Yoshikawa T . Inhibitory effects of FUT-175, a new synthetic protease inhibitor, on intravascular hemolysis by human serum in mice. Int J Immunopharmacol. 1987; 9(5):533-7. DOI: 10.1016/0192-0561(87)90120-2. View

Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N . Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res. 2000; 6(8):3297-303. View

Katayama S, Tateno C, Asahara T, Yoshizato K . Size-dependent in vivo growth potential of adult rat hepatocytes. Am J Pathol. 2001; 158(1):97-105. PMC: 1850269. DOI: 10.1016/S0002-9440(10)63948-X. View

Sugihara K, Kitamura S, Yamada T, Ohta S, Yamashita K, Yasuda M . Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun. 2001; 281(5):1093-9. DOI: 10.1006/bbrc.2001.4464. View

Dandri M, Burda M, Torok E, Pollok J, Iwanska A, Sommer G . Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001; 33(4):981-8. DOI: 10.1053/jhep.2001.23314. View

Imaoka S, Hayashi K, Hiroi T, Yabusaki Y, Kamataki T, Funae Y . A transgenic mouse expressing human CYP4B1 in the liver. Biochem Biophys Res Commun. 2001; 284(3):757-62. DOI: 10.1006/bbrc.2001.5055. View

Mercer D, Schiller D, Elliott J, Douglas D, Hao C, Rinfret A . Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7(8):927-33. DOI: 10.1038/90968. View

Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y . Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos. 2001; 29(10):1316-24. View

10.

Hwang D, Chae K, Shin D, Hwang J, Lim C, Kim Y . Xenobiotic response in humanized double transgenic mice expressing tetracycline-controlled transactivator and human CYP1B1. Arch Biochem Biophys. 2001; 395(1):32-40. DOI: 10.1006/abbi.2001.2542. View

11.

Asahina K, Sato H, Yamasaki C, Kataoka M, Shiokawa M, Katayama S . Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver. Am J Pathol. 2002; 160(6):2191-205. PMC: 1850835. DOI: 10.1016/S0002-9440(10)61167-4. View

12.

Morgan K, French S, Morgan T . Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology. 2002; 36(1):122-34. DOI: 10.1053/jhep.2002.33720. View

13.

Inagi R, Miyata T, Maeda K, Sugiyama S, Miyama A, Nakashima I . FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett. 1991; 27(1):49-52. DOI: 10.1016/0165-2478(91)90243-4. View

14.

Sandgren E, Palmiter R, Heckel J, Daugherty C, Brinster R, Degen J . Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell. 1991; 66(2):245-56. DOI: 10.1016/0092-8674(91)90615-6. View

15.

Zietkiewicz E, Labuda M, Sinnett D, Glorieux F, Labuda D . Linkage mapping by simultaneous screening of multiple polymorphic loci using Alu oligonucleotide-directed PCR. Proc Natl Acad Sci U S A. 1992; 89(18):8448-51. PMC: 49937. DOI: 10.1073/pnas.89.18.8448. View

16.

Leemann T, Transon C, Dayer P . Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci. 1993; 52(1):29-34. DOI: 10.1016/0024-3205(93)90285-b. View

17.

Miyagawa S, Shirakura R, Matsumiya G, Fukushima N, Nakata S, Matsuda H . Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation. 1993; 55(4):709-13. DOI: 10.1097/00007890-199304000-00004. View

18.

Hamatani K, Matsuda Y, Araki R, Itoh M, Abe M . Cloning and chromosomal mapping of the mouse DNA-dependent protein kinase gene. Immunogenetics. 1996; 45(1):1-5. DOI: 10.1007/s002510050159. View

19.

Heid C, Stevens J, Livak K, Williams P . Real time quantitative PCR. Genome Res. 1996; 6(10):986-94. DOI: 10.1101/gr.6.10.986. View

20.

Tateno C, Yoshizato K . Growth and differentiation in culture of clonogenic hepatocytes that express both phenotypes of hepatocytes and biliary epithelial cells. Am J Pathol. 1996; 149(5):1593-605. PMC: 1865270. View